Abbott touts long-term efficacy for dissolvable Esprit BTK stent

Abbott has unveiled positive long-term data for its Esprit below-the-knee (BTK) stent in treating the most severe form of peripheral artery disease (PAD).

The data, which was presented as a late-breaking clinical trial at the Vascular InterVentional Advances (VIVA) 2024 meeting, demonstrated that Abbott’s device offered sustained benefits over balloon angioplasty.